Inward, Upward, Forward
CHILD TRAUMA THERAPY
KETAMINE-assisted
Psychotherapy
My practice is closed and I'm working full-time at Sunstone Therapies in Rockville, MD. Please fill out this form if you're interested in volunteering for psychedelic therapy clinical trials. Thanks!
​
When prescribed by a doctor and used in conjunction with psychotherapy, ketamine can be a safe and effective treatment for a variety of mental health conditions, including depression, PTSD/Complex PTSD, anxiety disorders, traumatic grief, and more. It can be particularly helpful in treating suicidal feelings and hopelessness. I collaborate with an experienced psychiatrist to complete a comprehensive intake and evaluation. Together, we will determine if ketamine-assisted therapy may be a beneficial treatment for you.
After several preparatory therapy sessions to establish trust, determine treatment goals, and orient you to the experience, you will take your ketamine prescription during a three-hour guided journey and therapy session in a safe and comfortable treatment room. Therapy after each journey supports the healing and integration process. The length of treatment with ketamine-assisted psychotherapy will vary, but we generally start with intake, 2-3 prep sessions, and 1 dosing session. If that session goes well, we proceed to 3, and if that goes well, we proceed to 5-6, with integration sessions in between.
​
If you're interested in scheduling a free consultation for KAP, please complete this secure form.
​
I completed my training with Polaris Insight Center. More information about ketamine can be found at the Ketamine Research Institute and the Ketamine Research Foundation.
​
Curious what a KAP session is like? Here's an interview with me in
The Philadelphia Inquirer in December 2022.
MDMA-assisted
PSYCHOTherapy
I'm a MAPS-trained and certified MDMA-assisted therapist. Currently, I am participating as a study therapist at an Expanded Access clinical site. Phase 3 trials have been completed. Hopefully, this treatment will be approved by the FDA and available more widely in Fall 2024. In the interim, please see MAPS Clinical Trial website to learn about the research and opportunities to participate in Expanded Access programs and other clinical trials.
